Kimia Biosciences Ltd

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 July 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 01 September 2026, providing investors with the latest comprehensive view of the company’s position.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 July 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 August 2026, providing investors with the latest perspective on the company’s position.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 July 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained bearish momentum in the Pharmaceuticals & Biotechnology sector.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating as of 27 Jul 2026, reflecting deteriorating fundamentals and a shift to bearish technical indicators. The micro-cap pharmaceutical company’s financial performance has weakened significantly, while valuation and technical trends have also contributed to the negative outlook.

Kimia Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook amid persistent fundamental challenges. While the company’s financial performance remains under pressure, recent technical indicators have improved, prompting a reassessment of its near-term prospects.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 June 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 21 July 2026, providing investors with the latest view of the company’s position in the market.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 July 2026, providing investors with the latest insights into its performance and outlook.

Kimia Biosciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, persistent financial weakness, and a shift in technical momentum, signalling heightened risks for investors in this micro-cap pharmaceutical company.

Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 3 June 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Kimia Biosciences Ltd has seen its investment rating downgraded from Strong Sell to Sell as of 3 June 2026, reflecting deteriorating financial performance and mixed technical signals. Despite a modest uptick in daily share price, the company faces significant challenges across quality, valuation, financial trends, and technical indicators, prompting a reassessment of its market standing within the Pharmaceuticals & Biotechnology sector.

The 50-day moving average has crossed above the 200-day moving average for Kimia Biosciences Ltd, signalling a golden cross on 2 Jun 2026. Yet, the stock declined 1.35% on the same day, while monthly technical indicators remain bearish. This juxtaposition of signals calls for a detailed examination of the cross’s reliability.

Kimia Biosciences Ltd., a micro-cap pharmaceutical company specialising in bulk drug manufacturing, reported a dramatic 81.41% quarter-on-quarter decline in net profit for Q4 FY26, posting ₹0.37 crores compared to ₹1.99 crores in Q4 FY25. The sharp earnings contraction occurred despite relatively stable revenue performance, with net sales declining 28.87% year-on-year to ₹27.20 crores. The stock, currently trading at ₹36.50 with a market capitalisation of ₹168.00 crores, has struggled over the past year, delivering negative returns of 27.01% whilst the broader pharmaceuticals sector gained 9.25%.

Kimia Biosciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 09 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.